Videos
Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.
Nazli Dizman, MD, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma.
Key opinion leaders present an overview of first-line immune checkpoint inhibitor combination regimens specifically tailored for patients with favorable-risk metastatic renal cell carcinoma.
Medical experts examine the case of a 61-year-old male patient with a history of low-volume, indolent metastatic clear cell renal cell carcinoma, who has undergone left nephrectomy and adrenalectomy.
Adrienne Waks, MD, discusses the unmet needs in early-stage HER2-positive breast cancer.
Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.
Medical experts explore how improved hemoglobin levels with luspatercept treatment impact overall well-being and daily functioning, with insights from the post-hoc analysis of the COMMANDS study revealing relationships between hemoglobin levels and quality of life.
Medical experts examine the role of luspatercept as a first-line treatment for anemia in lower-risk MDS patients, including those with RS+/RS- and serum EPO ≤200 mU/L, and discuss its efficacy and potential benefits for this population.
Yeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.
Binod Dhakal, MD, MS, discusses why patients could benefit from earlier use of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.
Bhavana Pothuri, MD, discusses the biggest unmet needs for patients with endometrial cancer.
Aman Chauhan, MD, discusses the mechanism and benefits of lutetium oxodotreotide.
In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses brexucabtagene autoleucel for relapsed/refractory B-cell ALL.
Laura Huppert, MD, discusses a real-world study looking at the implications for using sequential ADCs in patients with breast cancer.
Mikkael A. Sekeres MD, MS, discusses the primary differences between imetelstat and other treatments available for patients with low- to intermediate-1 risk myelodysplastic syndromes.
Meredith McKean, MD, discusses a novel mRNA therapy for the treatment of solid tumors.
Nausheen Ahmed, MD, discusses the guidelines for monitoring patients after receiving CAR T-cell therapy.
Regina Barragan-Carrillo, MD, discusses a pilot study evaluating the use of camu camu in combination with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.